

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Op2jXdwRgJPYbSFOqODoe9d7UflOkEa9DyL9lccU0UUkwONLHhFyrw+28oLloXMS oyv7eBjnjPHAAdUSqyKJBQ== 0000895813-98-000099.txt : 19980413 0000895813-98-000099.hdr.sgml : 19980413 ACCESSION NUMBER: 0000895813-98-000099 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980410 SROS: AMEX SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-50777 FILM NUMBER: 98591489 BUSINESS ADDRESS: STREET 1: 30 ROCKEFELLER PLAZA STREET 2: SUITE 4515 CITY: NEW YORK STATE: NY ZIP: 10112 BUSINESS PHONE: 2129576600 MAIL ADDRESS: STREET 1: 30 ROCKEFELLER PLAZA STREET 2: SUITE 4515 CITY: NEW YORK STATE: NY ZIP: 10112 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 19940606 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GLOBAL CAPITAL MANAGEMENT INC/MN CENTRAL INDEX KEY: 0001034884 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 601 CARLSON PARKWAY STREET 2: SUITE 200 CITY: MINNETONKA STATE: MN ZIP: 55305 MAIL ADDRESS: STREET 1: 601 CARLSON PARKWAY STREET 2: SUITE 200 CITY: MINNETONK STATE: MN ZIP: 55305
SC 13G/A
1

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Amendment No. 1)

Under the Securities Exchange Act of 1934

Information to be Included in Statements Filed Pursuant
To 240.13d-1(b), (c) and Amendments Thereto Filed
Pursuant to 240.13d

Sheffield Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

8212 3D309
(CUSIP Number)

March 27, 1998
(Date of Event Which
Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).

CUSIP NO. 8212 3D309 13G (Amendment No. 1) Page 2 of 5 Pages

- 1) Names of Reporting Persons/I.R.S. Identification Nos. of
Above Persons

Global Capital Management, Inc./FEIN 41-1625323

- 2) Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐

(b) ☐

- 3) SEC Use Only

- 4) Citizenship or Place of Organization

Delaware

Number of Shares Beneficially Owned by Each Reporting Person With:

- 5) Sole Voting Power

611,530

- 6) Shared Voting Power

0

- 7) Sole Dispositive Power

611,530

8) Shared Dispositive Power

0

9) Aggregate Amount Beneficially Owned by Each Reporting Person

611,530

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

[]

11) Percent of Class Represented by Amount in Row (9)

4.7%

12) Type of Reporting Person (See Instructions)

CO

CUSIP NO. 8212 3D309 13G (Amendment No. 1) Page 3 of 5 Pages

SCHEDULE 13G
AMENDMENT NO. 1

ITEM 1. (a) Name of Issuer:

Sheffield Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices:

30 Rockefeller Plaza
Suite 4515
New York, New York 10112

ITEM 2. (a) Name of Person Filing:

Global Capital Management, Inc.

(b) Address of Principal Business Office:

602 Carlson Parkway
Suite 200
Minnetonka, Minnesota 55305

(c) Citizenship:

Delaware

(d) Title of Class of Securities:

Common Stock

(e) CUSIP Number:

8212 3D309

ITEM 3. If this statement is filed pursuant to Rule 13d-1(c),
check this box:

☒ [X]

ITEM 4. Ownership

(a) Amount Beneficially Owned:

611,530

(b) Percent of Class:

4.7%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote

611,530

CUSIP NO. 8212 3D309 13G (Amendment No. 1) Page 4 of 5 Pages

(ii) Shared power to vote or to direct the vote

0

(iii) Sole power to dispose or to direct the
disposition of

611,530

(iv) Shared power to dispose or to direct the
disposition of

0

ITEM 5. Ownership of Five Percent or Less of a Class

If this Statement is being filed to report the fact that as
of the date hereof the reporting person has ceased to be the
beneficial owner of more than 5 percent of the class of
securities, check the following ☒ [X].

ITEM 6. Ownership of More Than Five Percent on Behalf of Another Person

No Change

ITEM 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding

Company

Not Applicable

ITEM 8. Identification and Classification of Members of the Group

Not Applicable

ITEM 9. Notice of Dissolution of Group

Not Applicable

ITEM 10. Certification

No Change

CUSIP NO. 8212 3D309 13G (Amendment No. 1) Page 5 of 5 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete
and correct.

Date: April 8, 1998

GLOBAL CAPITAL MANAGEMENT, INC.

By: /s/ John D. Brandenburg

Name: John D. Brandenburg

Title: Vice President

-----END PRIVACY-ENHANCED MESSAGE-----